Abstract
Targeted immunization or attacks of large-scale networks has attracted significant attention by the scientific community. However, in real-world scenarios, knowledge and observations of the network may be limited thereby precluding a full assessment of the optimal nodes to immunize (or remove) in order to avoid epidemic spreading such as that of current COVID-19 epidemic. Here, we study a novel immunization strategy where only n nodes are observed at a time and the most central between these n nodes is immunized (or attacked). This process is continued repeatedly until 1 − p fraction of nodes are immunized (or attacked). We develop an analytical framework for this approach and determine the critical percolation threshold pc and the size of the giant component P∞; for networks with arbitrary degree distributions P(k). In the limit of n → ∞ we recover prior work on targeted attack, whereas for n = 1 we recover the known case of random failure. Between these two extremes, we observe that as n increases, pc increases quickly towards its optimal value under targeted immunization (attack) with complete information. In particular, we find a new scaling relationship between |pc(∞) − pc(n) | and n as |pc(∞) − pc(n)| ~ n−1 exp(−αn). For Scale-free (SF) networks, where P(k) ~ k−γ, 2 < γ < 3, we find that pc has a transition from zero to non-zero when n increases from n = 1 to order of logN (N is the size of network). Thus, for SF networks, knowledge of order of logN nodes and immunizing them can reduce dramatically an epidemics.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://arxiv.org/pdf/2004.00825.pdf
Funding Statement
Italian Ministry of Foreign Affairs and International Cooperation jointly with the Israeli Ministry of Science, Technology, and Space (MOST); the Israel Science Foundation, ONR, the Japan Science Foundation with MOST, BSF-NSF, ARO, the BIU Center for Research in Applied Cryptography and Cyber Security, and DTRA (Grants no. HDTRA1-14-1-0017 and HDTRA-1-19-1-0016) for financial support.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the available data and algorithms can be got by contacting the author.